Updates are available Correction dated 2023-03-22
Click to view Correction: https://doi.org/10.1038/s41467-023-37367-2
-
Authors
Fong, Youyi
Huang, Yunda https://orcid.org/0000-0003-1546-6172
Benkeser, David https://orcid.org/0000-0002-1019-8343
Carpp, Lindsay N. https://orcid.org/0000-0003-0333-5925
Áñez, Germán https://orcid.org/0000-0001-5361-3001
Woo, Wayne
McGarry, Alice
Dunkle, Lisa M.
Cho, Iksung
Houchens, Christopher R.
Martins, Karen
Jayashankar, Lakshmi
Castellino, Flora
Petropoulos, Christos J. https://orcid.org/0000-0001-5496-8090
Leith, Andrew
Haugaard, Deanne
Webb, Bill
Lu, Yiwen
Yu, Chenchen
Borate, Bhavesh
van der Laan, Lars W. P.
Hejazi, Nima S. https://orcid.org/0000-0002-7127-2789
Randhawa, April K. https://orcid.org/0000-0003-2652-3734
Andrasik, Michele P.
Kublin, James G.
Hutter, Julia
Keshtkar-Jahromi, Maryam https://orcid.org/0000-0001-8686-1036
Beresnev, Tatiana H.
Corey, Lawrence https://orcid.org/0000-0002-2179-2436
Neuzil, Kathleen M. https://orcid.org/0000-0001-9480-2714
Follmann, Dean https://orcid.org/0000-0003-4073-0393
Ake, Julie A.
Gay, Cynthia L. https://orcid.org/0000-0002-3620-3059
Kotloff, Karen L.
Koup, Richard A.
Donis, Ruben O.
Gilbert, Peter B. https://orcid.org/0000-0002-2662-9427
,
,
,
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UM1 AI68635, UM1 AI68614, UM1 AI68635, R37AI054165)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 11 August 2022
Accepted: 28 December 2022
First Online: 19 January 2023
Change Date: 22 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-37367-2
Competing interests
: All authors have completed the ICMJE uniform disclosure form at . P.B.G., Y.F., Y.H., D.B., Y.L., C.Y., B.B., L.W.P.v.d.L., A.K.R., M.P.A., J.G.K., L.C., and L.N.C. declare support (in the form of grant payments to their institutions) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) for the submitted work. Y.H. additionally declares contract payments to her institution within the past 36 months from the World Health Organization to conduct statistical analysis work related to COVID-19 vaccines (outside the scope of the current work), as well as direct payment (approved by her institute) within the past 36 months from Worcester HIV Vaccine for participation on a Data Safety Monitoring Board or Advisory Board. L.D., G.A., I.C., W.W., and A.M. are stockholders and employees at Novavax, Inc. C.J.P. declares support from BARDA and the US Centers for Disease Control within the past 36 months, for SARS-CoV-2 nAb testing for vaccine trials and surveillance studies, respectively, and is a shareholder in Labcorp (LH) and in Novavax (NVAX). N.S.H. declares a grant from the National Science Foundation within the past 36 months paid to his institution. K.M.N. declares grants within the past 36 months from Pfizer to her institution to conduct clinical trials of COVID-19 vaccines (but receives no salary support from these grants), as well as grants from the NIH to participate in the overall organization of COVID-19 vaccine trials and for participation in vaccine trials. K.L.K. declares support in the form of grant payments to her institution for the submitted work; serving as the PREVENT-19 Trial co-chair, CoVPN, with salary support from the NIH paid to her institution within the past 36 months; as well as PCR Cepheid and Abbott equipment for volunteer testing from CoVPN within the past 36 months (payments to her institution; will be returned). C.L.G. is a site Principal Investigator and a CoVPN protocol co-chair for the Novavax phase 3 trial. Her institution receives grant funding from NIH that includes salary support for her from NIAID for these activities. All other authors declare no support from any organization for the submitted work, no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.
